Recently, at the Intel Life Science Information Technology Forum 2016, a biometric acceleration platform called GTX One emerged, triggering a new industry view of the precision medical industry. The GTX One Acceleration System, which allows full FPGA-free computing power through algorithmic innovations, is equivalent to compressing a supercomputer into a small box; an FPGA accelerator card calculates up to 60 high-performance Xeon CPU servers Performance, greatly reducing the calculation time of biological information data. In fact, the biomedical industry is experiencing rapid growth through the combination of biological data with the healthcare industry. Intel's Intel BioIT Partners in Beijing is expected to complete a series of accurate medical procedures such as gene sequencing in 24 hours by 2020 - medical analysis - development of medical solutions and more. Precision medical and genetic sequencing are in full swing In the next five years, the global precision medical market will grow rapidly. According to the report of Southwest Securities, the global precision medical market will reach nearly 60 billion U.S. dollars in 2015 and a growth rate of 15% in 2015-2020, representing the growth of the pharmaceutical industry 3-4 times. In 2013, the market for gene sequencing was about 4.5 billion USD, with a CAGR of 21.2% from 2013 to 2018, while CAGR for China and India from 2012 to 2017 was 20-25%. From the medical technology point of view, precision medical can not be separated from the gene sequencing, there is a close relationship between the two. As for the rapid development of precision medicine in the world, it mainly benefits from the following three major factors. 1, the policy of strong support. Last year, the United States President Barack Obama announced in his 2015 State of the Union address: It will focus on precision medical development and invest 215 million U.S. dollars to establish a database and genetic screening. In China, favorable policies aimed at precision medicine are also appearing frequently. The Ministry of Science and Technology has even held the country's first expert meeting on precision medical strategies and plans to invest 60 billion yuan in precision medicine by 2030. Good news on policy greatly stimulated the relevant enterprises and medical institutions to invest human and financial resources to develop precision medical treatment. 2, the rise of genetic testing technology, has greatly promoted the rapid development of precision medical treatment. Compared with traditional medical technologies, precision medical treatment is not limited to the treatment of diseases. It has higher accuracy and efficiency in reducing the incidence of diseases and effectively preventing and treating the patient's condition. 3, With the continuous improvement of living standards, people are paying more and more attention to their own health. Especially for China, which is entering the process of population aging, the medical issue is becoming an increasingly important issue for the whole society. People's demand for precision medicine is also on the rise. Precise medical treatment still need to undergo nine nine eighty-one difficult However, throughout the country, the current popularization of precision medical services is not always easy. In fact, there are still many pain points in the whole industry. The first problem facing precision medicine is the problem of data collection. For many users, the data of their personal health information is confidential and they are not willing to disclose their health data to others. This has created some difficulties for precision medical treatment. Precision medical needs are based on a large amount of data. Without these data bases, accurate medical treatment can hardly be accurate. The second problem is the cost of the problem. Although the cost of gene sequencing is much lower than before, the cost of gene sequencing has not yet reached the level of popularization at this stage, and the vast majority of precision medical projects require high costs. Small medical institutions, it is difficult to bear. In addition, genetic testing and molecular targeted therapies are also expensive. The third challenge is for physicians and many small and medium-sized healthcare facilities, where precision medicine becomes part of day-to-day health care, these doctors need profound molecular genetics and biochemistry skills, not only to interpret the genetic test results but also It is important to understand how this information corresponds to later treatment or prophylaxis and to accurately communicate this information to the patient. A survey of doctors at Peking Union Medical College Hospital last year showed that doctors scored an average of 2.1 points (4 out of 4) on individual knowledge of genetics. The fourth problem is the payment of precision medical problems. Precision medical price can be accepted by ordinary people, this also needs to be considered. If most people can not afford accurate medical drugs, precision medical care will eventually be difficult to reach the mass market. In addition, the coverage of medical insurance is also a crucial step in medical insurance. The fifth challenge is how to differentiate the heterogeneity of the patient population. Even if the distinction is made, it also needs to involve the pharmaceutical industry. How to develop target-specific and even gene-specific drugs for specific groups is not so easy. Many aspects of the drug from clinical application to clinical application need to be considered. Nimonic is a registered trademark of Special Metals Corporation that refers to a family of nickel-based high-temperature low creep superalloys. Nimonic alloys typically consist of more than 50% nickel and 20% chromium with additives such as titanium and aluminium. nimonic 80a bolts,nimonic bolts,nimonic 80a fasteners Jiangsu Seonjip Technology Co.,Ltd. , https://www.seonjip.com
The main use is in gas turbine components and extremely high performance reciprocating internal combustion engines. The Nimonic family of alloys was first developed in the 1940s by research teams at the Wiggin Works in Hereford, England, in support of the development of the Whittle jet engine.
Due to its ability to withstand very high temperatures, Nimonic is ideal for use in aircraft parts and gas turbine components such as turbine blades and exhaust nozzles on jet engines, for instance, where the pressure and heat are extreme. It is available in different grades, including Nimonic 75, Nimonic 80A, and Nimonic 90. Nimonic 80a was used for the turbine blades on the Rolls-Royce Nene and de Havilland Ghost, Nimonic 90 on the Bristol Proteus, and Nimonic 105 on the Rolls-Royce Spey aviation gas turbines. Nimonic 263 was used in the combustion chambers of the Rolls-Royce/Snecma Olympus 593 used on the Concorde supersonic airliner. The heads of the exhaust valves as well as the turbine wheel of its Rajay turbocharger for the Corvair Spyder turbo engine were made of Nimonic 80A. Most Saab cars with high output turbos use exhaust valves made of Nimonic 80A as well.
Nimonic 75 has been certified by the European Union as a standard creep reference material.